Table 2 Univariate followed by multivariate analysis of factors associated with clinical remission at week 8 in patients with IBD (n = 184).

From: Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

 

Univariate analysis

Multivariate analysis

Variables

OR (95% CI)

P-value

OR (95% CI)

P-value

Sex (male)

1.21 (0.61–2.40)

0.580

  

Age (years)

0.09 (0.02–0.39)

0.001

0.32 (0.05–1.77)

0.192

BMI (kg/m2)

2.05 (0.15–28.17)

0.559

  

Current smoker

1.39 (0.49–3.97)

0.531

  

Disease (CD/UC)

1.79 (0.92–3.48)

0.084

1.90 (0.90–4.02)

0.089

Disease duration

0.17 (0.05–0.58)

0.005

0.27 (0.06–1.18)

0.082

Anti-cytokine biologics

(Anti-TNF/UST)

2.21 (1.04–4.71)

0.039

2.34 (1.01–5.40)

0.045

Anti-TNF exposure

0.67 (0.33–1.33)

0.257

  

Concomitant drugs

 Corticosteroids

0.82 (0.41–1.63)

0.580

  

 Immunomodulators

0.66 (0.34–1.31)

0.245

  

0w-LRG (µg/mL)

0.26 (0.06–1.13)

0.072

0.12 (0.02–0.68)

0.016

0w-CRP (mg/dL)

0.68 (0.05–8.18)

0.768

  

0w-Alb (g/dL)

3.63 (0.61–21.60)

0.156

  
  1. IBD inflammatory bowel disease, OR odds ratio, CI confidence interval, BMI Body mass index, CD Crohn’s disease, UC ulcerative colitis, TNF tumor necrosis factor, UST ustekinumab, LRG leucin-rich alpha-2 glycoprotein, 0w-LRG serum LRG level at week 0, CRP C-reattive protein, 0w-CRP serum CRP level at week 0, Alb albumin, 0w-Alb serum Albumin level at week 0.
Back to article page